Fan Lan, Wang Guo, Wang Lian-Sheng, Chen Yao, Zhang Wei, Huang Yuan-Fei, Huang Rui-Xue, Hu Dong-Li, Wang Dan, Zhou Hong-Hao
Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Hu-nan 410078, China.
Acta Pharmacol Sin. 2007 Oct;28(10):1685-92. doi: 10.1111/j.1745-7254.2007.00617.x.
To explore the potential interactions between yin zhi huang (YZH) and omeprazole, a substrate of CYP3A4 and CYP2C19.
Eighteen healthy volunteers, including 6 CYP2C19*1/1, 6 CYP2C191/*2 or 3 and 6 CYP2C192/*2 were enrolled in a 2-phase, randomized, crossover clinical trial. In each phase, the volunteers received either placebo or 10 mL YZH oral liquid, 3 times daily for 14 d. Then all the patients took a 20 mg omeprazole capsule orally. Blood samples were collected up to 12 h after omeprazole administration. Plasma concentrations of omeprazole and its metabolites were quantified by HPLC with UV detection.
After 14 d of treatment of YZH, plasma omeprazole significantly decreased and those of omeprazole sulfone and 5-hydroxyomeprazole significantly increased. The ratios of the area under the plasma concentration-time curves from time 0 to infinity (AUC(0-infinity) of omeprazole to 5-hydroxyomprazole and those of omeprazole to omeprazole sulfone decreased by 64.80%+/-12.51% (P=0.001) and 63.31%+/-18.45% (P=0.004) in CYP2C19*1/1, 57.98%+/-14.80% (P=0.002) and 54.87%+/-18.42% (P=0.003) in CYP2C191/*2 or 3, and 37.74%+/-16.07% (P=0.004) and 45.16%+/-15.54% (P=0.003) in CYP2C192/2, respectively. The decrease of the AUC(0-infinity) ratio of omeprazole to 5-hydroxyomprazole in CYP2C191/1 and CYP2C191/*2 or 3 was greater than those in CYP2C192/*2 (P=0.047 and P=0.009).
YZH induces both CYP3A4-catalyzed sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole leading to decreases in plasma omeprazole concentrations.
探讨茵栀黄(YZH)与细胞色素P450 3A4(CYP3A4)和细胞色素P450 2C19(CYP2C19)底物奥美拉唑之间的潜在相互作用。
18名健康志愿者,包括6名CYP2C191/1、6名CYP2C191/2或3以及6名CYP2C192/*2,参与一项两阶段、随机、交叉临床试验。在每个阶段,志愿者接受安慰剂或10 mL茵栀黄口服液,每日3次,共14天。然后所有患者口服20 mg奥美拉唑胶囊。在服用奥美拉唑后12小时内采集血样。采用高效液相色谱-紫外检测法对血浆中奥美拉唑及其代谢产物的浓度进行定量分析。
茵栀黄治疗14天后,血浆中奥美拉唑显著降低,而奥美拉唑砜和5-羟基奥美拉唑显著升高。在CYP2C191/1中,从时间0至无穷大的血浆浓度-时间曲线下面积(AUC(0-无穷大))中奥美拉唑与5-羟基奥美拉唑的比值以及奥美拉唑与奥美拉唑砜的比值分别降低了64.80%±12.51%(P = 0.001)和63.31%±18.45%(P = 0.004);在CYP2C191/2或3中分别降低了57.98%±14.80%(P = 0.002)和54.87%±18.42%(P = 0.003);在CYP2C192/*2中分别降低了37.74%±16.07%(P = 0.004)和45.16%±15.54%(P = 0.003)。CYP2C